diseas
exacerb
observ
pig
challeng
virul
porcin
reproduct
respiratori
syndrom
viru
prrsv
follow
immunis
recombin
subunit
prrsv
vaccin
produc
e
coli
eighteen
anim
divid
three
experiment
group
group
immunis
twice
im
day
apart
group
b
act
posit
control
challeng
immunis
group
c
neg
control
pig
group
b
challeng
day
second
immunis
group
anim
follow
challeng
three
pig
given
exhibit
sever
clinic
sign
posit
control
includ
respiratori
distress
progress
weightloss
although
statist
signific
sever
diseas
exhibit
group
anim
may
suggest
previou
immunis
contributori
factor
mechan
find
remain
unclear
associ
could
establish
sever
diseas
nonneutralis
antibodi
concentr
tissu
viral
load
immunis
pig
major
envelop
protein
subunit
vaccin
porcin
reproduct
respiratori
syndrom
viru
prrsv
result
enhanc
clinic
diseas
follow
experiment
challeng
introduct
porcin
reproduct
respiratori
syndrom
prr
characteris
reproduct
failur
sow
respiratori
distress
pig
age
rossow
caus
agent
prr
viru
prrsv
small
envelop
rna
viru
classifi
within
arterivirida
famili
cavanagh
viral
genom
consist
kb
long
linear
polyadenyl
rna
encod
nine
open
read
frame
orf
orf
encod
protein
replicas
polymeras
activ
orf
encod
virusassoci
protein
glycosyl
protein
encod
orf
major
compon
viru
envelop
meulenberg
et
al
associ
develop
neutralis
antibodi
host
protect
gonin
et
al
meulenberg
ostrowski
et
al
plagemann
b
key
target
design
novel
vaccin
overcom
safeti
problem
associ
modifi
live
vaccin
mengel
et
al
limit
efficaci
inactiv
vaccin
nielsen
et
al
prieto
et
al
scortti
et
al
experiment
vaccin
express
nativ
modifi
either
alon
combin
protein
develop
includ
dna
vaccin
pirzadeh
dea
kwang
et
al
barfo
et
al
xue
et
al
fang
et
al
jiang
et
al
bacteri
vaccin
mycobacterium
bovi
bcg
e
coli
express
recombin
protein
pirzadeh
dea
basto
et
al
recombin
viral
vaccin
baculoviru
et
al
pseudorabi
viru
qiu
et
al
jiang
et
al
adenoviru
gagnon
et
al
kheyar
et
al
jiang
et
al
recent
repliconbas
vaccin
mogler
et
al
jiang
et
al
howev
despit
develop
larg
number
vaccin
candid
studi
mice
pig
indic
use
result
limit
protect
best
partial
reduct
viraemia
tissu
viral
load
lack
protect
attribut
induct
weak
immun
respons
usual
insuffici
prevent
infect
viral
challeng
especi
challeng
heterogen
charact
although
vaccin
develop
date
demonstr
littl
protect
efficaci
report
advers
effect
increas
lesion
sever
infect
pig
immunis
e
coli
recombin
fusion
protein
pirzadeh
dea
advers
effect
occasion
found
follow
use
genet
engin
viral
vaccin
includ
equin
infecti
anaemia
wang
et
al
herp
ghiasia
et
al
influenza
heinen
et
al
virus
present
studi
report
diseas
exacerb
pig
previous
immunis
prrsv
subunit
vaccin
produc
e
coli
follow
challeng
prrsv
experiment
procedur
approv
anim
ethic
committe
universidad
complutens
de
madrid
eighteen
crossbr
piglet
prrsvseroneg
herd
randomli
divid
three
group
six
hous
isol
pen
concret
floor
automat
water
system
region
prrsv
amplifi
rtpcr
et
al
prior
clone
commerci
plasmid
prseta
invitrogen
gener
plasmid
use
express
recombin
protein
e
coli
de
plyss
compet
e
coli
cell
transfect
exponenti
cultur
transform
bacteria
induc
optic
densiti
od
nm
ad
mm
isopropylbetadthiogalactopyranosid
iptg
cultur
media
h
cultur
cell
lyse
separ
sdspage
band
correspond
excis
gel
electroelut
natur
elut
protein
determin
sdspage
analysi
follow
western
blot
use
hyperimmun
prrsvspecif
porcin
serum
aprr
protein
concentr
purifi
antigen
prepar
determin
spectrophotometri
sixth
passag
porcin
alveolar
macrophag
pam
strain
spain
use
templat
amplif
region
prrsv
strain
belong
lelystadlik
cluster
type
prrsv
experiment
challeng
immunis
pig
carri
seventh
passag
field
strain
pam
also
belong
lelystadlik
cluster
european
strain
et
al
forsberg
et
al
nucleotid
sequenc
strain
spain
deposit
genbank
access
number
dq
ident
strain
deposit
genbank
access
number
dq
name
spain
predict
amino
acid
sequenc
correspond
protein
ident
strain
align
nucleotid
sequenc
prrsv
strain
illustr
fig
sampl
collect
viral
challeng
evalu
use
pam
cultur
prieto
et
al
serum
neutralis
sn
assay
perform
cell
clone
highli
permiss
prrsv
deriv
cell
line
kim
et
al
atgagatgttctcacaaattggagcgtttcttgactcctcactcttgcttctggtggctt
spain
atgagatgttctcacaaattggagcgtttcttgactcctcactcttgcttctggtggcct
spain
tttttgctgtgtaccggcttgtcttggtcctttgtcgatggcaacgacagcagctcgaca
spain
tttttgctgtgtaccggcttgtcttggtcctttgtcgatggcgacgacaacagctcgaca
spain
taccaatacatatataatttgacgatatgcgagctgaatgggaccgaatggttgtccagc
spain
taccaatacatatataatttgacgatatgcgagctgaatgggaccaattggttgtccagc
spain
cattttgactgggcagtcgagacctttgtgctttacccggttgccactcatatcctttca
spain
cattttgactgggcagtcgagacctttgtgctttacccggttgccactcatatcctttca
spain
ctgggttttctcacaacaagccatttttttgatgcgctcggtctcggcgctgtgtccact
spain
ctgggttttctcacaacaagccatttttttgatgcgctcggtcttggcgctgtgtccatt
spain
acaggatttgttggcgggcggtatgtactcagcagcgtgtacggcgcttgtgctttcgca
spain
acaggatttgttggcgggcggtatgtactcagcagcatgtacggcgcttgtgctttcgca
spain
gcgctcgtatgttttgtcatccgcgctgctaaaaattgcatggcttgccgttatgcccgt
spain
gcgctcgtatgttttgtcatccgtgctgctaaaaattgcatggcttgccgttatgcccgt
spain
acccggtttaccaacttcattgtggacgaccgggggaggatccatcgatggaagtctcca
spain
acccggtttactaacttcattgtggacgaccgggggaggatccatcgatggaagtctcca
spain
atagtggtagagaaattgggcaaagctgaagtcggtggcgacctcgtcaccatcaaacat
spain
atagtggtagagaaattgggcaaancngaagtcggtggcgacctcgtcaccattaaacat
spain
gtcgtcctcgaaggggttaaagctcaacccttgacgaggacttcggctgagcaatgggaa
spain
gtcgtcctggaaggggttaaagctcaacccttgacgaggacttcggccgagcaatgggaa
spain
gcctag
spain
gcctag
studi
three
experiment
group
group
six
pig
number
immunis
twice
im
day
prior
challeng
day
lg
ml
incomplet
freund
adjuv
day
prior
experiment
inocul
day
lg
ml
incomplet
freund
adjuv
first
immunis
dose
given
pig
day
old
follow
acclimatis
period
day
six
pig
group
b
number
posit
control
thu
experiment
challeng
vaccin
group
c
pig
number
neg
control
neither
vaccin
challeng
three
week
follow
second
immunis
pig
group
b
inocul
intranas
ml
pam
cultur
lysat
contain
tissu
cultur
infecti
dose
tcid
prrsv
strain
pig
group
c
inocul
intranas
day
ml
uninfect
pam
cultur
lysat
clinic
sign
food
intak
evalu
daili
pig
follow
vaccin
experiment
inocul
respect
clinic
sign
grade
use
score
system
adapt
et
al
sign
evalu
includ
lethargi
anorexia
skin
discolour
sneez
cough
labour
abdomin
breath
respiratori
rate
tabl
serum
sampl
collect
pig
day
vaccin
variou
timepoint
postvaccin
pv
postchalleng
pc
serum
store
use
viru
isol
determin
prrsv
antibodi
titr
pig
euthanas
day
viru
inocul
examin
post
mortem
sampl
lung
tonsil
liver
kidney
spleen
submandibular
retropharyng
superfici
inguin
lymph
node
collect
store
use
viru
isol
sampl
process
previous
describ
prieto
et
al
inocul
onto
pam
monolay
duplic
cell
incub
min
facilit
adsorpt
monolay
wash
twice
dulbecco
modifi
eagl
medium
dmem
fresh
dmem
supplement
fetal
bovin
serum
fb
ad
cell
incub
day
humidifi
atmospher
contain
co
strain
ad
dmem
final
concentr
tcid
ml
ie
tcid
well
posit
control
batch
pam
minimum
sensit
infect
well
tcid
introduc
use
virusfre
dmem
fb
use
neg
control
presenc
cytopath
effect
cpe
characterist
prrsv
determin
day
postinocul
cpe
observ
rtpcr
carri
confirm
presenc
prrsv
et
al
viral
titr
determin
describ
scortti
et
al
calcul
describ
reed
muench
express
tcid
g
tissu
sampl
tcid
ml
serum
fluid
sampl
serum
sampl
examin
prrsvspecif
antibodi
use
commerci
elisa
civtestsui
prr
hipra
laboratori
serum
sampl
collect
day
pig
immunis
day
challeng
day
experi
termin
day
test
use
neutralis
assay
perform
cultur
yoon
et
al
tissu
sampl
collect
post
mortem
fix
neutral
buffer
formalin
dispatch
dr
j
segal
centr
de
recerca
en
sanitat
anim
barcelona
spain
histopatholog
examin
determin
porcin
circoviru
type
infect
statu
tissu
paraffinembed
lm
thick
section
cut
stain
use
haematoxylin
eosin
potenti
presenc
evalu
use
situ
hybridis
rosel
et
al
possibl
secondari
bacteri
pulmonari
infect
assess
use
routin
bacteriolog
cultur
occurr
clinic
sign
mean
daili
weight
gain
entir
period
pc
evalu
signific
use
kruskalw
nonparametr
dunn
multipl
comparison
test
student
test
use
assess
signific
differ
rectal
temperatur
prior
challeng
differ
viral
neutralis
antibodi
titr
sampl
point
analys
use
oneway
analysi
varianc
duncan
multipl
rang
test
clinic
sign
viral
titr
record
anim
convert
approxim
area
curv
auc
use
trapezoid
rule
hennen
auc
comput
day
challeng
end
experi
day
case
clinic
sign
result
data
compar
use
kruskalw
nonparametr
dunn
multipl
comparison
test
auc
valu
viraemia
compar
use
oneway
analysi
varianc
duncan
multipl
rang
test
test
carri
use
spss
softwar
result
consid
statist
signific
p
advers
reaction
immunis
observ
pig
experiment
group
remain
clinic
normal
viru
inocul
point
moder
sever
clinic
sign
exhibit
anim
group
b
clinic
sign
sever
pig
group
posit
control
b
fig
highest
mean
clinic
score
record
pig
group
day
pc
three
pig
exhibit
sever
clinic
sign
includ
lethargi
anorexia
mild
tachypnoea
labour
breath
pig
number
present
sign
day
pc
respect
strike
sign
sever
weight
loss
result
significantli
lower
daili
weight
gain
group
rel
two
group
fig
signific
decreas
daili
weight
gain
observ
group
mostli
due
effect
pig
lost
gday
pig
gain
gday
pc
howev
due
larg
individu
variat
clinic
score
daili
weight
gain
within
group
differ
found
statist
signific
pig
group
b
develop
pyrexia
defin
rectal
bodi
temperatur
least
one
day
pc
mean
bodi
temperatur
correl
clinic
score
fig
result
viru
isol
serum
sampl
collect
pc
detail
tabl
pig
group
b
viraem
day
pc
end
experi
except
pig
neg
day
viru
found
sampl
collect
pig
group
c
statist
signific
differ
auc
group
b
would
anticip
pig
challeng
group
statist
significantli
higher
auc
valu
group
c
pig
p
differ
mean
viral
titr
serum
sampl
group
b
statist
signific
day
pc
result
viru
isol
tissu
sampl
summaris
tabl
prrsv
detect
least
one
tissu
sampl
pig
group
b
viru
recov
tissu
sampl
group
c
pig
statist
signific
differ
found
group
b
term
viru
tissu
distribut
load
elisa
sn
test
neg
serum
sampl
pig
prior
immunis
day
challeng
pig
group
seroconvert
detect
elisa
although
neither
neutralis
antibodi
pig
group
b
c
remain
seroneg
challeng
postchalleng
group
b
pig
found
seroconvert
elisa
increas
antibodi
titr
note
pig
group
statist
significantli
higher
titr
found
group
rel
group
b
anim
day
pc
p
statist
signific
differ
observ
group
b
sn
respons
pc
data
shown
group
c
pig
exhibit
macroscop
microscop
lesion
group
b
anim
mild
gross
lesion
includ
moder
lymph
node
enlarg
congest
especi
mediastin
mesenter
node
signific
microscop
lesion
record
pig
similar
moder
lymph
node
enlarg
congest
observ
three
pig
group
moder
subacut
interstiti
pneumonia
characteris
alveolar
septal
thicken
mononuclear
cell
infiltr
fig
graph
illustr
mean
rectal
temperatur
experiment
group
day
day
postchalleng
porcin
reproduct
respiratori
syndrom
viru
red
squar
group
vaccin
protein
challeng
green
triangl
group
b
challeng
mauv
squar
group
c
vaccin
challeng
result
viru
isol
porcin
serum
sampl
collect
postchalleng
porcin
reproduct
respiratori
syndrom
viru
group
vaccin
protein
challeng
b
challeng
c
vaccin
challeng
posit
result
repres
infect
titr
log
tcid
ml
observ
microscop
three
group
pig
number
microscop
evid
infect
detect
situ
hybridis
develop
safe
effect
vaccin
prrsv
infect
remain
challeng
signific
prioriti
pig
product
industri
sever
promis
candid
fail
deliv
effect
protect
like
due
fact
even
viru
elicit
weak
strainspecif
immun
respons
lager
et
al
b
prieto
et
al
given
strain
prrsv
greater
potenti
induc
neutralis
crossreact
antibodi
other
set
assess
subunit
vaccin
base
protein
one
prrsv
strain
might
induc
protect
howev
protect
close
relat
virul
prrsv
strain
observ
pig
immunis
protein
demonstr
induc
clinic
sign
tissu
viral
load
pc
lack
protect
afford
vaccin
prrsv
attribut
inabl
elicit
robust
immun
respons
signific
antigen
divers
viru
lager
et
al
b
prieto
et
al
given
possibl
neutralis
antibodi
play
role
develop
protect
immun
interest
note
none
vaccin
anim
present
studi
develop
detect
level
antibodi
prior
challeng
two
pig
develop
specif
antibodi
day
pv
somewhat
unexpectedli
sever
clinic
sign
includ
respiratori
distress
anorexia
encount
vaccin
posit
control
anim
given
clinic
present
import
rule
confound
infect
quintana
et
al
vaccineenhanc
diseas
report
numer
envelop
virus
includ
flavivirus
alphavirus
poxvirus
bunyavirus
rhabdovirus
coronavirus
herpesvirus
reovirus
porterfield
burk
one
commonli
propos
mechan
explain
advers
effect
antibodydepend
enhanc
ade
viru
replic
nonneutralis
antibodi
induc
immunis
bind
viru
enhanc
target
cell
infect
particularli
monocyt
macrophag
enhanc
antibodi
demonstr
serum
prrsvinfect
pig
yoon
et
al
well
hivinfect
human
homsi
et
al
sivinfect
macaqu
montefiori
et
al
visna
virusinfect
sheep
jolli
et
al
caprin
arthritisenceph
virusinfect
goat
mcguir
et
al
furthermor
nonneutralis
igg
prrsv
also
incrimin
increas
level
durat
prrsv
viraemia
yoon
et
al
pirzadeh
dea
found
sever
lesion
pig
challeng
wildtyp
strain
prrsv
vaccin
e
coli
recombin
fusion
protein
develop
nonneutralis
antibodi
time
challeng
nonimmunis
control
present
studi
although
nonneutralis
antibodi
demonstr
anim
seroconvert
challeng
detect
level
neutralis
antibodi
correl
antibodi
level
sever
diseas
pc
establish
immunis
pig
develop
nonneutralis
antibodi
challeng
exhibit
enhanc
clinic
sign
find
inconsist
ade
although
definit
associ
antibodi
reactiv
enhanc
diseas
alway
establish
raab
et
al
case
affect
anim
measur
level
nonneutralis
antibodi
time
infect
typic
correl
sever
clinic
sign
viru
burden
observ
ade
diseas
found
studi
although
two
anim
sever
affect
persist
high
viral
titr
pig
exhibit
mild
clinic
sign
also
consist
high
viraemia
experiment
period
howev
must
also
consid
high
level
viru
replic
necessari
ultim
insuffici
compon
ade
raab
et
al
immunopatholog
mechan
cell
respons
may
play
vaccineinduc
diseas
exacerb
describ
influenza
heinen
et
al
respiratori
syncyti
matsuda
et
al
virus
excess
product
proinflammatori
cytokin
especi
interferona
tumour
tabl
result
viru
isol
porcin
tissu
sampl
collect
necropsi
day
postchalleng
porcin
reproduct
respiratori
syndrom
viru
group
vaccin
protein
challeng
b
challeng
c
vaccin
challeng
posit
result
repres
infect
titr
log
tcid
ml
necrosi
factor
tnf
correl
lung
patholog
case
number
viral
infect
van
reeth
nauwynck
interestingli
tnfa
product
link
weight
loss
system
diseas
case
respiratori
syncyti
influenza
viru
infect
hussel
et
al
cytokin
respons
also
implic
immunopatholog
process
associ
bovin
human
respiratori
syncyti
viru
coxsacki
viru
infect
boelen
et
al
kishimoto
et
al
kalina
et
al
autoimmun
could
also
involv
piglet
infect
prrsv
develop
sever
hypergammaglobulinaemia
lymph
adenopathi
butler
et
al
work
requir
assess
mechan
involv
develop
advers
event
describ
current
studi
type
immunogen
use
studi
may
contribut
diseas
enhanc
pirzadeh
dea
also
use
recombin
fusion
protein
express
e
coli
found
sever
lesion
microscop
immunis
anim
advers
effect
immunis
report
previous
found
vaccin
studi
use
either
whole
viru
subunit
prrsv
protein
gagnon
et
al
barfo
et
al
basto
et
al
xue
et
al
kheyar
et
al
qiu
et
al
scortti
et
al
scortti
et
al
jiang
et
al
b
prieto
et
al
result
studi
demonstr
immunis
grow
pig
recombin
fusion
prrsv
protein
fail
provid
protect
subsequ
viral
challeng
appear
exacerb
diseas
howev
mechan
put
vaccineinduc
diseas
enhanc
remain
elucid
none
author
paper
financi
person
relationship
peopl
organis
could
inappropri
influenc
bia
content
paper
